Cardiovascular Risk Reduction After Renal Denervation According to Time in Therapeutic Systolic Blood Pressure Range
Authors:
Top Cited Papers
Open Access
- 7 November 2022
- Vol. 80 (20) , 1871-1880
Abstract
No abstract availableKeywords
This publication has 24 references indexed in Scilit:
- Effect of renal denervation on blood pressure in the presence of antihypertensive drugs: 6-month efficacy and safety results from the SPYRAL HTN-ON MED proof-of-concept randomised trialThe Lancet, 2018
- Blood pressure variability and risk of cardiovascular events and death in patients with hypertension and different baseline risksEuropean Heart Journal, 2018
- Relative and Combined Prognostic Importance of On-Treatment Mean and Visit-to-Visit Blood Pressure Variability in ONTARGET and TRANSCEND PatientsHypertension, 2017
- Catheter-based renal denervation in patients with uncontrolled hypertension in the absence of antihypertensive medications (SPYRAL HTN-OFF MED): a randomised, sham-controlled, proof-of-concept trialThe Lancet, 2017
- Blood pressure lowering for prevention of cardiovascular disease and death: a systematic review and meta-analysisThe Lancet, 2016
- First Report of the Global SYMPLICITY Registry on the Effect of Renal Artery Denervation in Patients With Uncontrolled HypertensionHypertension, 2015
- Effect of renal denervation on left ventricular mass and function in patients with resistant hypertension: data from a multi-centre cardiovascular magnetic resonance imaging trialEuropean Heart Journal, 2014
- Rationale and design of a large registry on renal denervation: the Global SYMPLICITY registryEuroIntervention, 2013
- Blood Pressure Control and Improved Cardiovascular Outcomes in the International Verapamil SR-Trandolapril StudyHypertension, 2007
- Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood PressureHypertension, 2003